CC-1088 explained

CC-1088 is a thalidomide analogue inhibitor of phosphodiesterase 4 that was being developed up to 2005 by Celgene Corp., for treating of inflammatory diseases and myelodysplastic syndromes.^[1] Apremilast (CC-10004) was found to be a preferable.^[2]

See also

• Apremilast
• Development of analogs of thalidomide

External links

• NCI Thesaurus

Notes and References

1. Current Opinion in Investigational Drugs. May 2005. 6. 5. 513–7. CC-1088 Celgene. K. Dredge. 15912966.
2. Molostvov G, Morris A, Rose P, Basu S, Muller G . The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures. British Journal of Haematology. February 2004 . 124. 3. 366–75. 14717786. 10.1046/j.1365-2141.2003.04777.x. free.